Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Name November 3, 2025 8:30 AM EST
Firm Individuals
Stephane Paquette – Vice President of Company Growth
Krish Krishnan – Founder, Chairman, President & CEO
Laurent Goux – Senior VP & GM of Europe
Suma Krishnan – Founder, President of R&D and Director
Kathryn Romano – Government VP & Chief Accounting Officer
Convention Name Individuals
Jiale Track – Jefferies LLC, Analysis Division
Ritu Baral – TD Cowen, Analysis Division
Gavin Clark-Gartner – Evercore ISI Institutional Equities, Analysis Division
Samantha Corwin – William Blair & Firm L.L.C., Analysis Division
Alexa Deemer – Cantor Fitzgerald & Co., Analysis Division
Morgan Lamberti – Goldman Sachs Group, Inc., Analysis Division
Presentation
Operator
Thanks for standing by, and welcome to the Krystal Biotech Third Quarter 2025 Earnings Name. [Operator Instructions] As a reminder, in the present day’s convention is being recorded. I might now like handy the convention over to your host, Stephane Paquette, Vice President of Company Growth. Please start.
Stephane Paquette
Vice President of Company Growth
Good morning, and thanks all for becoming a member of in the present day’s name. Earlier in the present day, we launched our monetary outcomes for the third quarter of 2025. The press launch is out there on our web site at www.krystalbio.com. We additionally filed our earnings 8-Okay and 10-Q with the SEC earlier in the present day. Becoming a member of me in the present day might be Krish Krishnan, Chairman and Chief Government Officer; Suma Krishnan, President of Analysis and Growth; Laurent Goux, Senior Vice President and Basic Supervisor for Europe; and Kate Romano, Chief Accounting Officer.
This convention name will and our responses to questions might include forward-looking statements. You might be cautioned to not depend on these forward-looking statements, that are primarily based on present expectations utilizing the data out there as of the date of this name and are topic to sure dangers and uncertainties that will trigger the corporate’s precise outcomes to vary materially from
